Clinical value of profunda femoral vein thrombosis clearance in endovascular treatment of acute lower extremity deep vein thrombosis
Journal Title: Journal of Surgery : Concepts & Practice - Year 2025, Vol 30, Issue 1
Abstract
[Objective] To evaluate the safety and efficacy of profunda femoral vein thrombosis clearance in endovascular treatment of acute lower [e] xtremity deep venous thrombosis (DVT). [Methods] From January 2022 to September 2023, clinical data of acute lower [e] xtremity DVT patients who underwent percutaneous mechanical thrombectomy (PMT) for profunda femoral vein thrombosis were retrospectively analyzed. The 12-month primary patency rate of iliofemoral vein and incidence of post-thrombotic syndrome(PTS) were analyzed. [Results] Twenty-two patients were included in the study, and all patients underwent PMT for profunda femoral vein thrombosis. Five patients were treated through the contralateral common femoral vein via crossover approach, and 17 patients were treated through the contralateral common femoral vein combined with the ipsilateral deep vein approach. The 12-month primary patency rate of iliofemoral vein was 90.9% (20/22), and the incidence of PTS was 9.1% (2/22). [Conclusions] For patients with acute lower [e] xtremity DVT undergoing endovascular treatment, PMT for profunda femoral vein thrombosis is safe and effective, achieving good primary patency of iliofemoral vein and low incidence of PTS.
Authors and Affiliations
Qihong NI, Jiaquan CHEN, Xiangjiang GUO, Meng YE, Lan ZHANG
Keywords
Related Articles
- EP ID EP765829
- DOI 10.16139/j.1007-9610.2025.01.11
- Views 13
- Downloads 0
Clinical study on comprehensive treatment of gallbladder cancer
Early detection of gallbladder cancer is difficult with poor prognosis in late stage. Although radical surgical treatment is the main method to cure gallbladder cancer at present, only less patients have radical surgery...
Current status and future perspective of hepatic artery infusion chemotherapy
The interpretation of Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update
Bone-modifying agents (BMAs), including bisphosphonate (BP) and denosumab, can reduce bone-related events caused by breast cancer bone metastasis. “Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breas...
Treatment strategies for subacute lower extremities deep vein thrombosis
In this article we primarily explored the treatment strategies for subacute lower extremity deep vein thrombosis (LEDVT). We introduced the definition, incidence, and clinical stage of DVT, emphasized the pathological ch...
Value of contrast-enhanced ultrasound in differentiating benign and malignant gallbladder lesions which diameter more than 1 cm
[Objective] To investigate the clinical value of contrast-enhanced ultrasound (CEUS) in differential diagnosis between benign and malignant gallbladder lesions which diameter more than 1 cm. [Methods] A retrospective a...